DESCOVY Rx
Viral infections  Only 4 drugs may be compared at once
Remove Selected
Compare Selected
Generic Name and Formulations:
Emtricitabine 200mg, tenofovir alafenamide 25mg; tabs.
Company:
Gilead Sciences, Inc.

Select therapeutic use: Viral infections
Indications for DESCOVY:
HIV-1 infection, in combination with other antiretroviral agents.

Limitations Of use:
Not for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in high-risk adults.

Adults and Children:
Test for HBV infection prior to initiation. <12yrs (<35kg): not established. ≥12yrs (≥35kg): 1 tab once daily. Severe renal impairment (CrCl <30mL/min): not recommended.

Warnings/Precautions:
Not for treating chronic HBV infection; test for HBV before starting therapy and closely monitor patients co-infected with HBV and HIV for several months after stopping treatment (discontinuing therapy may exacerbate HBV infection); if appropriate, initiate anti-hepatitis B therapy may be warranted (especially in those with advanced liver disease or cirrhosis). Suspend therapy if lactic acidosis or hepatotoxicity (eg, hepatomegaly, steatosis) occurs. Monitor CrCl, urine glucose, urine protein, serum phosphorus (in patients at risk for chronic renal disease); discontinue if significant renal dysfunction or Fanconi syndrome occurs). History of pathologic fracture or risk factors of osteoporosis or bone loss: consider monitoring bone mineral density (BMD); calcium/vitamin D supplement may be beneficial. Severe hepatic impairment. Pregnancy. Nursing mothers: not recommended.

Interactions:
Concomitant drugs that strongly affect P-gp activity may lead to changes in TAF absorption. Avoid with concurrent or recent use of nephrotoxic agents. Concomitant tipranavir/ritonavir, antimycobacterials (eg, rifabutin, rifampin, rifapentine), St. John's wort: not recommended. May be antagonized by anticonvulsants (eg, carbamazepine, oxcarbazepine, phenobarbital, phenytoin; consider alternatives. May be potentiated by drugs that decrease renal function or compete for active tubular secretion (eg, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides, NSAIDs).

Pharmacological Class:
Nucleoside analogues (reverse transcriptase inhibitors).

Adverse Reactions:
Nausea; decreased BMD, new onset or worsening renal impairment, immune reconstitution syndrome.

Note:
Register pregnant patients in the Antiretroviral Pregnancy Registry (APR) by calling (800) 258-4263.

Generic Availability:
NO

How Supplied:
Tabs—30